secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0001023024-25-000044
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma posts record Q1 revenue $197.1M (+43%); raises FY2025 guidance
-------------------------------------------------------------------------

- Record Q1 net revenue $197.1M (+43.4% YoY); Rare Disease $69.0M (Cortrophin Gel $52.9M, +43.1%).
- Record adjusted non-GAAP EBITDA $50.7M (+34.9%); adjusted diluted EPS $1.70, up from $1.21 YoY.
- Generics revenue $98.7M (+40.5%) driven by new launches including first-to-market prucalopride.
- Raised 2025 guidance: net revenue $768M-$793M, EBITDA $195M-$205M, adjusted EPS $6.27-$6.62.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000044/0001023024-25-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000044/ani-20250509.htm
  HTML page:      https://secwatch.observer/filing/0001023024-25-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer